数十年重症医学随机对照试验:随机证据改变了什么、纠正了什么、仍待解决的问题
核心发现:早期生物学与血流动力学试验暴露了综合征性危重症中还原论策略的局限;方案驱动方法改善了及时性与一致性,但后续实用性试验显示,高质量常规诊疗建立后,僵化目标和侵入性算法常无额外获益。近期试验挑战「干预强度越大结局越好」的假设,强调时机、疾病阶段、基线风险、异质性和治疗相关伤害。未来需以生物学为基础、情境敏感、聚焦生存、康复和长期功能的试验。
要点
- 早期血流动力学与生物学试验显示,生理学合理的干预在综合征性危重症中未能改善以患者为中心的结局。
- 方案驱动方法可改善及时性和一致性,但高质量常规诊疗建立后,僵化目标和侵入性算法常无额外获益。
- 近期试验挑战「干预强度越大结局越好」的假设,强调时机、疾病阶段、基线风险、异质性和治疗相关伤害。
- 现代重症RCT不仅明确什么有效,也明确什么可以缩减、延迟、避免或选择性应用。
- 未来试验应聚焦有意义的生存、康复和长期功能,而非仅生理终点。
适用人群与场景
- 成人重症医学(ICM)患者,涵盖血流动力学支持、机械通气、肾脏替代治疗、抗菌治疗、营养、血糖控制、输血和镇静等场景。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及具体药物剂量或处置流程,仅指出应关注时机、疾病阶段、基线风险、异质性和治疗相关伤害,并考虑缩减、延迟、避免或选择性应用干预。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 关键发现:早期生物学和血流动力学试验暴露了综合征性危重症中还原论策略的局限;方案驱动方法改善了及时性和一致性,但后续实用性试验显示,高质量常规诊疗建立后,僵化目标和侵入性算法常无额外获益。
- 近期试验挑战「干预强度越大结局越好」的假设,强调时机、疾病阶段、基线风险、异质性和治疗相关伤害。
- 现代重症RCT不仅明确什么有效,也明确什么可以缩减、延迟、避免或选择性应用。
证据类型、等级与局限
- 证据类型:叙述性历史综述,非系统评价或RCT。
- 证据等级或推荐强度:原文未提及。
- 局限:原文未明确说明;作为叙述性综述,可能存在选择偏倚,未进行系统证据分级。
对床旁实践的改变
- 提示急诊/ICU医生:不应仅凭生理学合理性推广干预,需等待以患者为中心结局的RCT证据。
- 在高质量常规诊疗已建立的情况下,避免盲目追求僵化目标和侵入性算法。
- 对干预的时机、疾病阶段、基线风险、异质性和治疗相关伤害保持警觉,考虑缩减、延迟、避免或选择性应用。
- 原文未提及具体适用与不适用人群,常见陷阱为将生理终点改善误认为临床获益。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Randomised controlled trials (RCTs) have reshaped intensive care medicine (ICM), a discipline defined by acute, interacting organ failures, time-sensitive decisions, biological uncertainty, and heterogeneous recovery trajectories. Many interventions supported by strong physiological rationale failed to improve patient-centred outcomes, whereas durable advances often emerged from optimisation of supportive care, avoidance of iatrogenic harm, and reassessment of established practices.
METHODS: We conducted an interpretive historical review of landmark multicentre RCTs in adult ICM from the early 1990s onwards. PubMed searches, reference lists from major trials and reviews, and international guidelines were used to identify trials with conceptual influence on practice, guidelines, physiological reasoning, therapeutic strategy, research priorities, de-implementation, or outcome framing. Evidence was organised into overlapping paradigms rather than rigid chronological periods.
FINDINGS: Across haemodynamic support, mechanical ventilation, renal replacement therapy, antimicrobial treatment, nutrition, glucose control, transfusion, and sedation, landmark RCTs describe more than therapeutic expansion. Early biological and haemodynamic trials exposed the limits of reductionist strategies in syndromic critical illness. Protocol-driven approaches improved timeliness and consistency, but later pragmatic trials showed that rigid targets and invasive algorithms often added little once high-quality usual care was established. More recent trials challenge the assumption that greater intervention intensity improves outcomes, emphasising timing, disease phase, baseline risk, heterogeneity, patient selection, and treatment-related harm. Modern ICM RCTs have clarified not only what works, but what can be reduced, delayed, avoided, or applied selectively. Future progress requires biologically informed, context-sensitive trials focussed on meaningful survival, recovery, and long-term function.
参考来源
- Martin-Loeches I, Leone M, Coopersmith CM, et al. Decades of intensive care medicine trials: what randomised evidence has changed, corrected, and still questions to resolve. Intensive Care Med. 2026. PMID: 42593537. doi:10.1007/s00134-026-08579-z
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。